Federated Hermes Inc. Sells 381 Shares of HealthEquity, Inc. (NASDAQ:HQY)

Federated Hermes Inc. lowered its position in shares of HealthEquity, Inc. (NASDAQ:HQY) by 3.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,856 shares of the company’s stock after selling 381 shares during the period. Federated Hermes Inc.’s holdings in HealthEquity were worth $936,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in HealthEquity by 1.7% during the first quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company’s stock worth $715,783,000 after buying an additional 149,133 shares in the last quarter. Wasatch Advisors LP increased its stake in shares of HealthEquity by 8.3% in the 1st quarter. Wasatch Advisors LP now owns 7,409,080 shares of the company’s stock valued at $604,803,000 after purchasing an additional 569,249 shares during the last quarter. Motley Fool Asset Management LLC lifted its position in shares of HealthEquity by 3,001.0% during the 1st quarter. Motley Fool Asset Management LLC now owns 3,762,064 shares of the company’s stock worth $307,097,000 after buying an additional 3,640,748 shares during the last quarter. Stephens Investment Management Group LLC boosted its stake in HealthEquity by 4.6% in the fourth quarter. Stephens Investment Management Group LLC now owns 1,186,491 shares of the company’s stock valued at $78,664,000 after buying an additional 52,383 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in HealthEquity by 24.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,129,634 shares of the company’s stock valued at $74,895,000 after acquiring an additional 223,428 shares during the last quarter. 99.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on HQY shares. Royal Bank of Canada restated an “outperform” rating and issued a $92.00 price target on shares of HealthEquity in a research note on Wednesday, September 4th. JMP Securities reaffirmed a “market outperform” rating and set a $105.00 target price on shares of HealthEquity in a research note on Wednesday, September 4th. Robert W. Baird increased their price target on HealthEquity from $98.00 to $104.00 and gave the company an “outperform” rating in a research note on Tuesday, June 4th. Barrington Research restated an “outperform” rating and set a $105.00 price objective on shares of HealthEquity in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft increased their target price on HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $103.83.

HealthEquity Stock Performance

Shares of HQY stock opened at $79.53 on Friday. The firm has a 50 day moving average of $76.17 and a 200-day moving average of $79.32. The company has a market cap of $6.92 billion, a price-to-earnings ratio of 86.45, a price-to-earnings-growth ratio of 1.19 and a beta of 0.52. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51. HealthEquity, Inc. has a 52 week low of $61.81 and a 52 week high of $88.26.

Insider Buying and Selling at HealthEquity

In related news, Vice Chairman Stephen Neeleman sold 35,000 shares of HealthEquity stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $79.86, for a total value of $2,795,100.00. Following the completion of the sale, the insider now owns 89,769 shares of the company’s stock, valued at approximately $7,168,952.34. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO Jon Kessler sold 32,326 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $82.83, for a total value of $2,677,562.58. Following the sale, the chief executive officer now owns 232,176 shares in the company, valued at approximately $19,231,138.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Vice Chairman Stephen Neeleman sold 35,000 shares of HealthEquity stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $79.86, for a total value of $2,795,100.00. Following the transaction, the insider now owns 89,769 shares of the company’s stock, valued at approximately $7,168,952.34. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 75,031 shares of company stock valued at $6,103,625. Corporate insiders own 2.20% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.